Page last updated: 2024-08-16

troglitazone and efatutazone

troglitazone has been researched along with efatutazone in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Copland, JA; Fujiwara, K; Haugen, BR; Klopper, JP; Kreinest, PA; Kurakata, S; Marlow, LA; Smallridge, RC; Williams, SF; Wong, AK	1

Other Studies

1 other study(ies) available for troglitazone and efatutazone

Article	Year
Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene, 2006, Apr-13, Volume: 25, Issue:16 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Chromans; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor Proteins; Female; Humans; Mice; Paclitaxel; PPAR gamma; Thiazolidinediones; Thyroid Neoplasms; Troglitazone	2006

Article

Year

Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1.

Oncogene, 2006, Apr-13, Volume: 25, Issue:16

Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Chromans; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor Proteins; Female; Humans; Mice; Paclitaxel; PPAR gamma; Thiazolidinediones; Thyroid Neoplasms; Troglitazone

2006